In the registry-based, cohort study AvoidEx, data was collected from German healthcare insurance claims and Swedish medical records of COPD patients ≥40 years. All participants had their first COPD diagnosis during 2010-2017. Overall, 250,723 COPD patient from Germany and 27,178 COPD patients from Sweden were included. Patients were divided into 4 groups (i.e. none, 1 moderate, 1 severe, ≥ 2 moderate to severe) according to the baseline exacerbation 12 months pre-index (which is based on the exacerbation classification). The follow-up period lasted up to 9 years.
In German patients without baseline exacerbations, 19.0% (18.9-19.2%) had exacerbations after 1-year follow-up and 35.9% (35.7-36.1%) after 3 years. In Sweden, corresponding numbers were 22.5% (21.9-23.1%) and 39.4% (38.7-40.1%), respectively. After 3 years, cumulative exacerbation risk was 59.1% (58.5-59.7%), 58.1% (56.1-60.1%), and 84.1% (83.6-84.5%) in German patients with 1 moderate, 1 severe, and ≥2 moderate-to-severe exacerbations at baseline, respectively. Corresponding numbers in the Swedish population were 53.6% (51.7-55.5%), 66.6% (62.6-70.7%), and 84.1% (82.8-85.4%), respectively (see Figure). “As you can see, there is a stepwise increase: patients who had a lower exacerbation rate in the past had a lower risk of exacerbations in the future and the risk goes up depending on the exacerbation history,” explained Prof. Claus Vogelmeier (University Clinic Giessen and Marburg, Germany).
Figure: Results show that patients with previous exacerbations have a much higher risk of future exacerbations [1]

In total, more than 1 out of 3 patients without baseline COPD exacerbation experienced exacerbation(s) during the 3-year follow up. In addition, more than half of those with 1 moderate baseline exacerbation experienced subsequent exacerbation(s), with an even higher risk in patients with frequent or severe baseline exacerbations. Yet, even patients with only 1 moderate baseline exacerbation had more subsequent exacerbations compared with those without baseline exacerbations. Patients with no history of exacerbations had also a much longer time until the next subsequent exacerbation during follow-up.
“I think this data very nicely supports earlier data under very different circumstances, because this data used medical data and insurance data from a very big cohort. But all this information stresses that exacerbation history is a self-fulfilling prophecy for future events,” Prof. Vogelmeier concluded.
- Vogelmeier C. Risk of future exacerbations among COPD patients – A real-world register-based cohort study (AvoidEx). Abstract 4189, ERS International Virtual Congress 2020, 7-9 Sept.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Singing training effective as physical rehabilitation in COPD Next Article
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients »
« Singing training effective as physical rehabilitation in COPD Next Article
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients »
Table of Contents: ERS 2020
Featured articles
COVID-19 and the Lung
COVID-19 infections: Bronchoscopy provides additional diagnostic certainty
COVID-19 vaccines: An ongoing race
COVID-19: What is the risk of reinfection?
COVID-19 App: The Dutch experience
Secondary pulmonary fibrosis: a possible long-term effect of severe COVID-19
COVID-19 survivors benefit from structured follow-up
Early pulmonary rehabilitation post-COVID-19 aids recovery
Asthma – What's New
Mild asthma: A fundamental change in management
Dupilumab shows long-term efficacy in asthma patients
Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity
First-in-class tyrosine kinase inhibitor shows promise in severe asthma
Predicting individual effectiveness of biologics in severe asthma
IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps
Treatment according to genotype: The future of asthma therapy?
COPD – The Beat Goes On
The role of chronic symptoms as early biomarkers of COPD development
Urgent call for studies in COPD patients aged 40-60 years
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients
Exacerbation history is a reliable predictor of future exacerbations
Singing training effective as physical rehabilitation in COPD
Current prediction tools underestimate exacerbation risk of severe COPD patients
Exercise and Sleep: From Impaired Function to New Therapeutic Strategies
CPAP withdrawal has negative consequences for sleep apnoea patients
Physical activity improves AHI in sleep apnoea patients
The Tobacco Epidemic: From Vaping to Cannabis
Poly-use of nicotine products and cannabis: a deadly combination
E-cigarettes: A source of chronic lung inflammation
Social smoking: Do not underestimate the risks
Chronic Cough – State of the Art
LEAD study shows multiple phenotypes in many chronic cough patients
First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment
Lung Cancer Detection
Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis
Distinct changes in lung microbiome precede clinical diagnosis of lung cancer
Best of Posters
Smartphone-based cough detection helpful in predicting asthma deterioration
Reduced lung function associated with cognitive decline in the elderly
Longer hospital stay and fewer transplants for frail ILD patients
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy